ATAI Stock Slips After Blockbuster Week: Cathie Wood Calls $3.8B Lilly Deal ‘Well-Deserved’
ATAI Life Sciences stock slipped after a strong week, as ARKG sold 1.12 million shares. Cathie Wood praised Eli Lilly's $3.8 billion deal as a well-deserved return for shareholders.
Key Numbers
Shares of ATAI Life Sciences (NASDAQ: ATAI) slipped on Monday after a week of strong gains, following data showing that Cathie Wood's ARK Genomic Revolution ETF (ARKG) sold 1.12 million ATAI shares last week. However, ARKG still holds 3.19 million ATAI shares as of Friday.
Deal Details
Last week, Eli Lilly (NYSE: LLY) announced its acquisition of ATAI for $3.8 billion, sending ATAI shares soaring. Cathie Wood commented that the deal is a "well-deserved return for shareholders," noting that the price reflects the company's intrinsic value.
Context
The sale comes after ARKG realized significant gains from its ATAI investment, with the stock more than doubling after the deal announcement. However, selling a portion of the stake may indicate profit-taking or portfolio rebalancing.
What This Means for Investors
It remains to be seen whether the sale marks the beginning of a gradual exit from ATAI or just a minor adjustment. Investors are watching the deal's progress and its impact on both ATAI and LLY shares.
Frequently Asked Questions
Found this useful? Share it